Pipeline Database & Screener

Over 1000 entries in Phase 2, 3 or NDA development of small and mid-cap biotech companies listed on AMEX/NASDAQ.Generally no OTC companies are listed unless the upcoming catalyst is a PDUFA or Advisory Committee event. LARGE cap companies are generally NOT featured in the database unless it is a PDUFA or Advisory Committee event.

Company SCREENER also available to filter through financial and clinical data.

N.B. The short ratio is the number of shares sold short divided by the average daily volume, also known as the number of ”days to cover”.

Pipeline data are updated at the end of each trading day.

Financial data are currently not up to date due to issues with our provider. The SEARCH tool and SCREENER are currently not functioning for users of Internet Explorer. We hope to find fixes for both issues.

Showing 385 companies
Screener
Sort
Stage
Market Cap
Price
Short ratio
Relative Volume
Price to book
FDA Calendar
Company
Price
Change
Market Cap
Outstanding Shares
Short Ratio
Updated
$33.05
-1.35  -3.92%
$1.23B
37,200,000
1.77
08/20/2016
Tap to view 4 drugs
Drug Indication Stage News
Annexin V-128 Rheumatoid arthritis and ankylosing spondylitis Phase 1/2 Ongoing
Lutathera Inoperable progressive midgut NETs PDUFA PDUFA date under priority review December 28, 2016
Somakit-TATE Neuroendocrine tumor diagnosis Approved Approved June 1 2016
Somakit-TOC Neuroendocrine cancers MAA filed October 2015
$4.28
-0.06  -1.38%
$143.57M
33,545,000
13.60
08/14/2016
Tap to view 1 drug
Drug Indication Stage News
ABO-102 Sanfilippo syndrome type A (MPS IIIA) Phase 1/2 Phase 1/2 dosing initiated May 2016. Continues to enrol as of August 2016
$2.88
-0.02  -0.69%
$26.11M
9,066,000
7.79
08/14/2016
Tap to view 1 drug
Drug Indication Stage News
Gencaro - GENETIC-AF trial Chronic Heart Failure Phase 2b Phase 2b interim analysis due 2Q 2017
$3.66
-0.13  -3.43%
$200.55M
54,796,000
10.08
08/05/2016
Tap to view 2 drugs
Drug Indication Stage News
ARB-1467 Hepatitis B (HBV) Phase 2 Phase 2 single dose data due 3Q 2016, multiple dose data due 4Q 2016
TKM-PLK1 Hepatocellular carcinoma (HCC) Phase 1/2 Phase 1/2 data released July 2016. Intends to explore partnership opportunities to enable further study
$32.30
-0.16  -0.49%
$3.68B
114,005,000
11.11
08/13/2016
Tap to view 3 drugs
Drug Indication Stage News
Pimavanserin Alzheimer’s disease agitation Phase 2 Phase 2 trial to be initiated 2H 2016
Pimavanserin Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016
Pimavanserin Alzheimer’s disease psychosis Phase 2 Phase 2 top-line data due 4Q 2016
$8.60
+0  +0%
$1.18B
136,680,000
11.05
08/14/2016
Tap to view 3 drugs
Drug Indication Stage News
ACH-4471 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 interim data due by end of 2016
Odalasvir (ACH-3102) and sofosbuvir Hepatitis C (HCV) Phase 2b Phase 2b trial to be initiated 3Q 2016
Odalasvir (ACH-3102), simeprevir and ALS-335 Hepatitis C (HCV) Phase 2a Phase 2a top-line data due September 23 2016 at EASL
$24.48
+0.19  +0.78%
$1.13B
46,090,000
11.62
08/13/2016
Tap to view 3 drugs
Drug Indication Stage News
CVT-301 OFF episodes of Parkinson’s disease (PD) Phase 3 Phase 3 data due 1Q 2017
Dalfampridine Post stroke deficits Phase 3 Phase 3 data due 2H 2016
Tozadenant Parkinson’s disease (PD) Phase 3 To be acquired from Biotie Therapies Corp 2H 2016
$20.23
-0.59  -2.83%
$433.23M
21,415,000
9.51
08/02/2016
Tap to view 2 drugs
Drug Indication Stage News
A-101 Seborrheic keratosis (SK) Phase 3 Phase 3 data due 4Q 2016
A-101 Common warts (verruca vulgaris) Phase 2 Phase 2 data due 3Q 2016
$3.24
-0.09  -2.7%
$146.81M
45,312,000
16.60
08/16/2016
Tap to view 3 drugs
Drug Indication Stage News
ARX-04 (SAP302) Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury Phase 3 Phase 3 data released August 15 2016
ARX-04 (SAP303) moderate-to-severe acute pain following a surgical procedure Phase 3 Phase 3 top-line data due 3Q 2016, with potential NDA filing by end of 2016
Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery Phase 3 CRL Jul 26 2014. Additional clinical trial required. NDA Filing due by end of 2016
$1.32
+0.01  +0.77%
$14.14M
10,712,000
0.27
08/02/2016
Tap to view 1 drug
Drug Indication Stage News
CaPre (TRIFECTA trial) Hypertriglyceridemia Phase 2 Phase 3 planned
$6.92
-0.08  -1%
$489.83M
70,785,000
3.15
08/13/2016
Tap to view 6 drugs
Drug Indication Stage News
NY-ESO T-cell therapy Synovial sarcoma - cancer Phase 3 Phase 3 to be initiated mid 2017
NY-ESO T-cell therapy Ovarian cancer Phase 1/2 Further trials planned for 2H 2016
NY-ESO T-cell therapy Myxoid round cell liposarcoma (MRCLS) Phase 3 Clinical hold placed on pivotal study. Envisage initiation 4Q 2016 or 1Q 2017
NY-ESO T-cell therapy Myeloma Phase 1/2 Further trials planned for 1H 2017
NY-ESO T-cell therapy Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 initiated November 2015. Data are due 2017
NY-ESO T-cell therapy Melanoma Phase 1/2 Further trials planned for 2017
$4.98
+0.02  +0.4%
$137.26M
27,562,000
34.63
08/06/2016
Tap to view 3 drugs
Drug Indication Stage News
MDX (Metadoxine Extended Release (MG01CI)) Adult ADHD Phase 3 Data from second Phase 3 trial due by end of 2016
MDX (Metadoxine Extended Release (MG01CI)) Pediatric ADHD Phase 2a Phase 2b data released March 2015. Secondary cognitive measures did not produce statistically significant results. In discussions with FDA regarding future trials
MDX (Metadoxine Extended Release (MG01CI)) Fragile X Syndrome Phase 2 Phase 2 trial did not meet endpoints - June 2015. In discussions with FDA regarding Phase 3 trial
$5.38
-0.12  -2.19%
$69.33M
12,886,000
2.35
08/02/2016
Tap to view 1 drug
Drug Indication Stage News
RI-002 Primary Immune Deficiency Diseases CRL CRL issued July 29 2016. Third-party manufacturing issues cited.
$2.77
+0.02  +0.73%
$57.85M
20,886,000
3.79
08/14/2016
Tap to view 3 drugs
Drug Indication Stage News
APC-1000 Asthma/COPD Phase 2 Phase 3 planned
APC-3000 Allergic Rhinitis Phase 2 Phase 3 planned
Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. CRL CRL issued March 27 2015. NDA resubmitted. CRL issued again June 6, 2016. Intends to submit more data 2H 2016
$13.31
-0.41  -2.99%
$291.88M
21,929,000
8.51
08/05/2016
Tap to view 3 drugs
Drug Indication Stage News
ADS-5102 Multiple sclerosis (MS) Phase 2 Phase 2 data released early June 2016
ADS-5102 - EASE LID trial Levodopa-Induced Dyskinesia NDA Filing Phase 3 data released December 2015. NDA filing due 2016
Namzaric Moderate to severe dementia of the Alzheimer’s type. Approved Approved Dec 24 2014
$13.77
-0.79  -5.43%
$891.66M
64,754,000
18.64
08/14/2016
Tap to view 4 drugs
Drug Indication Stage News
CRS-207 Mesothelioma - cancer Phase 3 Development path to be announced 2H 2016
CRS-207 and GVAX Pancreas - ECLIPSE trial Pancreatic cancer Phase 2b Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial Pancreatic cancer Phase 2b Phase 2b interim data to be released 2H 2016
Epacadostat and CRS-207 - SEASCAPE Ovarian cancer Phase 1/2 Phase 1/2 dosing initiated March 2016
$3.68
-0.37  -9.14%
$152.16M
41,348,000
2.12
07/25/2016
Tap to view 1 drug
$11.82
-0.32  -2.64%
$405.97M
34,346,000
15.47
08/14/2016
Tap to view 6 drugs
Drug Indication Stage News
ADXS-HER2 HER2-driven malignancies - cancer Phase 1b Complete enrollment of Phase 1b dose-escalation study 1H 2016
ADXS-PSA and Keytruda Castrate-resistant prostate cancer Phase 1/2 Completed the first two dose-escalation cohorts and launched the third dose-escalation cohort in April 2016
Axalimogene filolisbac Anal cancer (FAWCETT) Phase 2 Phase 2 initiated June 2016
Axalimogene filolisbac - AIM2CERV Trial High-risk, locally advanced cervical cancer Phase 3 Phase 3 to commence 3Q 2016
Axalimogene filolisbac - GOG 0265 study Cervical cancer Phase 2 Phase 2 preliminary data released June 2016 at ASCO. Stage 2 enrollment to commence 3Q 2016
Axalimogene filolisbac + durvalumab Recurrent or refractory HPV-associated cervical cancer and head & neck cancer Phase 1/2 Phase 1/2 second dose-escalation cohort completed July 2016
$18.92
-0.12  -0.63%
$527.72M
27,892,000
14.24
08/04/2016
Tap to view 2 drugs
Drug Indication Stage News
Rhopressa Glaucoma NDA Filing NDA filing due 3Q 2016
Roclatan - Mercury trials Glaucoma Phase 3 Phase 3 Mercury 1 data due September 2016. Mercury 2 trial data due 2Q 2017
$3.62
+0  +0%
$35.98M
9,939,000
2.80
08/13/2016
Tap to view 2 drugs
Drug Indication Stage News
Macimorelin Acetate - Macrilen Adult Growth Deficiency Phase 3 CRL Nov 5 2014. Initiated Phase 3 trial in November 2015, to be completed 2016
Zoptrex Endometrial cancer Phase 3 Phase 3 trial to be completed 2016
$2.56
+0.03  +1.19%
$85.73M
33,487,000
5.74
08/14/2016
Tap to view 2 drugs
Drug Indication Stage News
AFM13 Hodgkin Lymphoma - Cancer Phase 1b Phase 1b update due end of 2016 or early 2017
AFM13 Hodgkin Lymphoma - Cancer Phase 2 Phase 2a monotherapy trial is currently being modified - August 2016
$38.08
-0.44  -1.14%
$1.45B
38,046,000
15.58
08/06/2016
Tap to view 6 drugs
Drug Indication Stage News
AG-120 Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer Phase 3 Phase 3 to be initiated 1H 2017
AG-120 IDH1 mutant positive cholangiocarcinoma - cancer Phase 2 Phase 2 to be initiated 2H 2016
AG-221 Advanced Hematologic Malignancies Phase 1/2 Interim data released December 2015
AG-221 Relapsed/Refractory IDH2 mutant-positive Acute Myeloid Leukemia Phase 1/2 Phase 1/2 enrolment completed May 2016
AG-221 - IDHENTIFY Refractory Acute myeloid leukemia (AML) - cancer Phase 3 Global Phase 3 study for AG-221 initiated October 2015. Continue to enrol through 2016
AG-348 Pyruvate kinase deficiency Phase 2 Phase 2 first data released at EHA meeting June 2016
$7.34
-0.22  -2.91%
$211.04M
28,752,000
6.76
08/14/2016
Tap to view 1 drug
Drug Indication Stage News
Twirla Contraceptive patch Phase 3 CRL issued 2013. Phase 3 to be completed 4Q 2016.
$14.54
-0.27  -1.82%
$614.37M
42,254,000
11.21
08/13/2016
Tap to view 1 drug
$3.78
+0.03  +0.8%
$100.85M
26,679,000
2.47
08/13/2016
Tap to view 2 drugs
Drug Indication Stage News
Plazomicin - CARE Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE) Phase 3 Phase 3 topline data due 1H 2017
Plazomicin - EPIC trial Complicated urinary tract infections (cUTI) Phase 3 Phase 3 top-line results due 1Q 2017
$8.09
+0.06  +0.75%
$148.05M
18,300,000
11.43
08/14/2016
Tap to view 2 drugs
Drug Indication Stage News
Vadadustat - INNO2VATE Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD) Phase 3 Phase 3 initiated August 2016. Enrollment to be completed by early 2018
Vadadustat - PRO2TECT Non-dialysis patients with anemia related to CKD (NDD-CKD) Phase 3 Phase 3 initiated January 2016. NDA to be filed 2019 assuming postive data
$31.81
+0.77  +2.48%
$1.60B
50,184,000
14.17
08/14/2016
Tap to view 2 drugs
$5.39
-0.08  -1.28%
$33.66M
6,245,000
2.61
08/13/2016
Tap to view 3 drugs
Drug Indication Stage News
NS2 Allergic conjunctivitis Phase 2 Phase 2/3 trial to begin 2H 2016. Data due 2H 2017
NS2 Noninfectious anterior uveitis Phase 2 Phase 2/3 to begin 2H 2016. Data expected mid-2018
NS2 Sjögren-Larsson Syndrome (SLS) Phase 2 Phase 2 data released August 2016
$1.56
+0.01  +0.65%
$71.38M
45,759,000
1.03
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
Iluvien Diabetic macular edema Approved Approved Sept 26 2014
$44.17
-0.29  -0.63%
$6.69B
151,556,000
4.82
08/14/2016
Tap to view 6 drugs
Drug Indication Stage News
ALKS 3831 - ENLIGHTEN-1 and ENLIGHTEN-2 Schizophrenia Phase 3 Pivotal trials initiated December 2015 and February 2016
ALKS 5461 Major depressive disorder Phase 2 Phase 3 data from first two trials did not meet their endpoints. FORWARD-5 data, the third of three trials, due by end of 2016
ALKS 6428 Opioid dependence Phase 3 Phase 3 initated September 2015
ALKS 8700 Multiple sclerosis (MS) Phase 3 Phase 3 trial to be initiated mid-2016 with data due 2018
Aristada Schizophrenia sNDA Filing Approved October 5 2015. sNDA filed for 2-month option August 8 2016
Aristada Schizophrenia Approved Approved October 5 2015. sNDA filing due 2H 2016
$69.35
-1.48  -2.09%
$5.94B
85,724,000
9.40
08/13/2016
Tap to view 7 drugs
Drug Indication Stage News
ALN-CC5 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1/2 Phase 1/2 initial data released June 11 2016 with Phase 2 trial to be initiated towards the end of 2016
ALN-GO1 Primary Hyperoxaluria Type 1 (PH1) Phase 1/2 Phase 1/2 initiated March 2016. Initial data September 24 2016
ALN-HBV Chronic hepatitis B virus (HBV) Phase 1/2 Phase 1/2 trial initiated July 2016. Data are due mid 2017
ALN-TTRsc02 ATTR amyloidosis Phase 1 Phase 3 to be initiated 2017 assuming positive Phase 1 initial data due end of 2016
Fitusiran Hemophilia Phase 3 Phase 3 program to be initiated early 2017
Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 data due mid 2017
Revusiran ENDEAVOUR ATTR in patients with familial amyloidotic cardiomyopathy (FAC) Phase 3 Phase 3 data due early 2018
$0.94
+0  +0%
$N/A
0
0.00
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
AZ-002 Acute repetitive seizures Phase 2 Phase 2a expected to be released 1H 2016
$24.02
-0.83  -3.34%
$820.38M
34,154,000
9.61
08/13/2016
Tap to view 2 drugs
Drug Indication Stage News
Feraheme Adults with iron deficiency anemia (IDA) Phase 3 Phase 3 dosing commenced March 2016. sNDA in late 2017.
Makena - single-dose vial Reduce the risk of preterm birth in women with a singleton pregnancy Approved Approved February 23 2016
$3.07
+0  +0%
$566.57M
184,551,000
11.41
08/04/2016
Tap to view 1 drug
Drug Indication Stage News
Vascepa REDUCE-IT outcomes trial High Triglycerides With Mixed Dyslipidemia Interim analysis due September or October 2016. Second interim analysis due 1H 2017
$48.72
-0.34  -0.69%
$719.94M
14,777,000
7.72
08/14/2016
Tap to view 2 drugs
$2.95
-0.09  -2.96%
$122.21M
41,427,000
8.71
08/13/2016
Tap to view 3 drugs
Drug Indication Stage News
Blisibimod IgA nephropathy Phase 2 Phase 2 primary endpoint not met
Blisibimod Lupus Phase 3 Missed primary endpoints in Phase 2b trial Jun 2012. Phase 3 final data due early 4Q 2016
Sollpura (liprotamase) Cystic fibrosis who suffer from exocrine pancreatic insufficiency Phase 3 Phase 3 initiated October 2015. Top-line data due 4Q 2016
$3.31
-0.04  -1.19%
$12.83M
3,876,000
0.69
07/25/2016
Tap to view 1 drug
$0.34
-0.02  -3.05%
$22.59M
66,350,000
6.53
08/05/2016
Tap to view 2 drugs
Drug Indication Stage News
RayVa Secondary Raynaud’s Phenomenon Phase 2b Phase 2b planned - seeking partnership
Vitaros Erectile dysfunction NDA Filing NDA to be resubmitted at earliest late 4Q 2016
$9.33
+0.28  +3.21%
$160.59M
17,212,000
16.54
08/14/2016
Tap to view 3 drugs
Drug Indication Stage News
AQX-1125 FLAGSHIP Chronic obstructive pulmonary disease (COPD) Phase 2 Phase 2 trail failed - July 2015
AQX-1125 KINSHIP Atopic dermatitis (AD) Phase 2 Phase 2 failed to demonstrate efficacy November 2015
AQX-1125 LEADERSHIP Bladder pain syndrome/interstitial cystitis (BPS/IC). Phase 3 Phase 2 trial did not meet endpoints - June 2015 but postive secondary endpoint data - August 2015. Phase 3 trial to commence 3Q 2016
$4.74
+0.18  +4.05%
$70.06M
14,781,000
1.89
08/14/2016
Tap to view 1 drug
Drug Indication Stage News
Pulmaquin - ORBIT-3 and ORBIT-4 Non-cystic fibrosis bronchiectasis (non-CF BE). Phase 3 Phase 3 data due by the end of 2016
$10.06
+0.45  +4.68%
$475.34M
47,250,000
6.26
08/13/2016
Tap to view 3 drugs
Drug Indication Stage News
RDX227675 Hyperkalemia Phase 3 Onset-of-action and Phase 3 trials to be initiated 4Q 2016 with data due 1H 2017 from onset-of-action trial.
Tenapanor Hyperphosphatemia in end-stage renal disease (ESRD) patients Phase 3 Phase 3 data due 1Q 2017
Tenapanor Constipation-predominant irritable bowel syndrome (IBS-C) Phase 3 Phase 3 trial initiated October 2015. Second trial initiated December 2015. Data from first trial due mid 2017, with data from second trial due later that year
$4.64
+0.12  +2.65%
$191.15M
41,196,000
6.56
08/14/2016
Tap to view 4 drugs
Drug Indication Stage News
AGS-003 Non-Small Cell Lung Cancer Phase 2 Phase 2 initiated 1Q 2016
AGS-003 Early stage renal cell carcinoma (RCC) - cancer Phase 2 Phase 2 initial data due 4Q 2016
AGS-003 ADAPT Trial Metastatic renal cell carcinoma (mRCC) Phase 3 Phase 3 overall survival analysis due 1H 2017
AGS-004 HIV Phase 2 Phase 2 second stage commenced dosing July 2016
$10.20
+0.18  +1.8%
$1.97B
192,713,000
6.02
08/14/2016
Tap to view 5 drugs
Drug Indication Stage News
AP32788 Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 enrolling as of July 2016
Brigatinib ALK+ non-small cell lung cancer (NSCLC) - front line Phase 3 Phase 3 trial initiated April 2016. Enrolment to be completed 2018
Brigatinib - ALTA trial Anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) NDA Filing NDA rolling submission filed June 2016. Submission to be completed 3Q 2016
Iclusig (ponatinib) Cancer - third line chronic-phase CML (CP-CML) Phase 2 Phase 2 dose ranging trial initiated August 2015. Preliminary data due end of 2016
Iclusig (ponatinib) Cancer - second line chronic-phase CML (CP-CML) Phase 3 Phase 3 enrolment to be completed in 2018
$4.98
-0.16  -3.11%
$324.90M
65,241,000
6.88
08/01/2016
Tap to view 1 drug
Drug Indication Stage News
YOSPRALA (PA32540/PA8140) Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers PDUFA PDUFA date September 14 2016
$1.63
+0.04  +2.52%
$396.51M
243,256,000
6.93
08/13/2016
Tap to view 4 drugs
Drug Indication Stage News
APD334 Ulcerative colitis Phase 2 Phase 2 data due 4Q 2016
APD371 Pain associated with Crohn’s disease Phase 2 Phase 2 to be initiated 2017
Lorcaserin Smoking cessation Phase 2 Phase 2 initiated March 2014. Data released Nov 2014
Ralinepag Pulmonary Arterial Hypertension Phase 2 Phase 2 data due mid 2017
$1.44
-0.01  -0.69%
$102.39M
71,106,000
1.03
08/04/2016
Tap to view 2 drugs
Drug Indication Stage News
ARQ 087 intrahepatic cholangiocarcinoma (iCCA) Phase 1/2 Phase 1/2 preliminary data released June 2016.
Tivantinib (ARQ 197) METIV-HCC trial Previously treated Inoperable Hepatocellular Carcinoma cancer Phase 3 Phase 3 SPA agreed upon. Dosage reduced following recommendation from DMC. Final analysis late 2016 or early 2017
$3.17
-0.06  -1.86%
$454.70M
143,439,000
14.71
08/13/2016
Tap to view 7 drugs
Drug Indication Stage News
ARRY 797 LMNA A/C-related dilated cardiomyopathy (DCM) Phase 2 Phase 2 data to be presented at the European Society of Cardiology on August 30, 2016
ARRY-520 (Filanesib) Refractory Multiple Myeloma Cancer Phase 2 Phase 2 interim data due 2016 but no plans to advance program
Binimetinib - COLUMBUS BRAF mutant melanoma cancer Phase 3 Phase 3 data due 3Q 2016
Binimetinib - MILO Recurrent low-grade serous ovarian cancer (LGSOC) Phase 3 Phase 3 trial discontinued April 2016
Binimetinib (NEMO) NRAS melanoma - cancer NDA Filing Announced NDA Filing June 30 2016
Encorafenib and cetuximab BRAF-Mutant Colorectal Cancer Phase 3 Phase 3 initiated June 2016. Enrolment to be completed 2018
Selumetinib - SELECT-1 Differentiated thyroid cancer Phase 3 Phase 3 trial did not meet its primary endpoint - August 2016
$6.88
-0.01  -0.15%
$417.96M
60,750,000
30.54
08/06/2016
Tap to view 2 drugs
Drug Indication Stage News
ARC-520 injection in combination with entecavir or tenofovir Chronic Hepititis B (HBV) Phase 2 Partial clinical hold placed by FDA in early Jan 2015. Phase 2 trial to proceed with lower doses than initially proposed. Dosing commenced January 2016
ARC-521 Chronic Hepititis B (HBV) Phase 1/2 Phase 1/2 initiated June 2016
$6.55
+0.11  +1.71%
$112.82M
17,225,000
5.78
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
VEN 307 (diltiazem cream) Anal fissures Phase 3 Phase 3 data from second trial did not meet primary endpoint - Feb 2014. Will not pursue future development
$17.49
-0.27  -1.52%
$439.49M
25,128,000
9.78
08/14/2016
Tap to view 1 drug
Drug Indication Stage News
TransCon Growth hormone deficiency in children Phase 3 Phase 3 initiated August 2016.
$2.73
-0.06  -2.15%
$123.99M
45,418,000
9.38
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
AST-VAC1 Acute myeloid leukemia (AML) Phase 2 Phase 3 planned for late 2017
$1.96
+0.02  +1.03%
$166.56M
84,982,000
21.18
07/25/2016
Tap to view 2 drugs
Drug Indication Stage News
Multistem Ischemic stroke Phase 2 Phase 2 data released mid April 2015. Endpoints not met.
Multistem Acute myocardial infarction Phase 2 Phase 2 enrolment but reported May 2016 that enrolment is slower than expected
$1.70
+0.04  +2.41%
$81.12M
47,717,000
6.03
08/14/2016
Tap to view 2 drugs
Drug Indication Stage News
Actimab-A Acute Myeloid Leukemia (AML) Phase 1/2 Phase 2 to be initiated 2H 2016
Iomab-B Hematopoietic Stem Cells Transplantation Phase 2 Phase 3 initiated June 2016
$0.24
-0.01  -2.45%
$9.47M
39,569,000
3.73
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
Fulvestrant Cuctal carcinoma in situ(DCIS) - invasive breast cancer Phase 2 Phase 2 initiated March 2016
$19.63
-0.51  -2.53%
$565.56M
28,811,000
14.06
08/14/2016
Tap to view 4 drugs
Drug Indication Stage News
CMV-CTL Refractory CMV Chorioretinitis or Meningoencephalitis Phase 2 Phase 2 data released at ASH 2015. Expects to meet with FDA during 4Q 2016 to discuss further development
EBV-CTL Epstein-Barr virus (EBV-PTLD) Phase 2 Pivotal trials to be initiated by the end of 2016
EBV-CTL Nasopharyngeal carcinoma (NPC) Phase 2 Phase 2 trial to be initiated 2017
PINTA 745 Protein-energy wasting Phase 2 Phase 2 endpoint not met December 2015
$1.45
+0.18  +14.17%
$224.83M
155,058,000
9.27
08/14/2016
Tap to view 2 drugs
Drug Indication Stage News
OTREXUP Rheumatoid arthritis (RA) Approved Approved Oct 14 2013
VIBEX QuickShot Testosterone deficiency NDA Filing Phase 3 data are due 3Q 2016. NDA to be filed late 2016.
$1.98
-0.05  -2.46%
$69.87M
35,286,000
3.52
08/16/2016
Tap to view 1 drug
$0.97
-0.02  -2.02%
$73.58M
75,859,000
3.01
08/05/2016
Tap to view 1 drug
Drug Indication Stage News
TIVO-3 - tivozanib Third line treatment of patients with renal cell cancer Phase 3 Phase 3 dosing commenced May 2016. Data due 1Q 2018
$1.33
-0.08  -5%
$51.39M
38,640,000
1.64
08/06/2016
Tap to view 4 drugs
Drug Indication Stage News
BTA074 5% topical gel Condyloma Phase 2 Phase 2 top-line data due 2H 2017
BTA585 Respiratory syncytial virus (RSV) Phase 2a Phase 2a initiated April 2016. Enrolment halted May 2016 due to safety issues
Laninamivir Octanoate - IGLOO Adults with symptomatic influenza A or B infection Phase 2 Phase 2 initiated Jun 2013. Topline data did not meet the primary endpoint - July 2014
Vapendavir - SPIRITUS trial Human rhinovirus (HRV) Phase 2b Phase 2b top-line data due 2H 2016
$3.14
-0.04  -1.26%
$112.13M
35,710,000
2.40
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
ANAVEX 2-73 Mild to moderate Alzheimer’s disease Phase 2a Phase 2a interim data released January 2016. Trial is ongoing. Additional Phase 2/3 trial planned
$16.08
-0.36  -2.19%
$1.59B
99,161,000
27.64
08/16/2016
Tap to view 4 drugs
Drug Indication Stage News
Intepirdine - HEADWAY-DLB Dementia with Lewy bodies (DLB) Phase 2b Phase 2b data due 2017
Intepirdine - MINDSET Alzheimer’s disease Phase 3 Phase 3 initiated October 2015. Data are due 2017
Nelotanserin DLB patients experiencing REM Behavior Disorder (RBD) Phase 2 Phase 2 data due 2017
Nelotanserin Visual hallucinations in subjects with Lewy body dementia Phase 2 Phase 2 data due 2H 2016
$7.44
+0.07  +0.95%
$142.47M
19,149,000
13.90
08/14/2016
Tap to view 5 drugs
Drug Indication Stage News
AXS-02 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017
AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3 Phase 3 to be initiated 4Q 2016 or 1Q 2017
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016
AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 planned
AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016
$2.45
-0.01  -0.15%
$45.64M
18,654,000
1.65
08/06/2016
Tap to view 1 drug
Drug Indication Stage News
NurOwn Amytrophic lateral sclerosis (ALS) Phase 2 Phase 2 data released July 2016. Pivotal trial planned
$4.10
-0.29  -6.61%
$302.17M
73,700,000
10.13
08/14/2016
Tap to view 3 drugs
Drug Indication Stage News
BCX4161 - OPuS-2 Hereditary angioedema Phase 2b Phase 2b data released February 2016 - primary endpoint not met
BCX7353 - APeX-1 Reduce or eliminate attacks in HAE patients Phase 2 Phase 2 screening has commenced - August 2016
Peramivir - Study 303 INFLUENZA ACUTE Approved Approved Dec 22 2014
$2.47
-0.04  -1.59%
$132.49M
53,639,000
9.59
08/05/2016
Tap to view 3 drugs
Drug Indication Stage News
BEMA Buprenorphine Pain Approved Approved October 26 2015
BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL Opioid dependence Approved Approved June 7 2014
Clonidine gel Painful diabetic neuropathy (PDN) Phase 2b Phase 3 trial failed to meet primary endpoint late March 2015. New trial initiated late 2015. Data due from Phase 2b trial 4Q 2016
$0.41
+0.01  +1.38%
$26.30M
64,148,000
0.07
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
BIOD-531 Type 2 diabetes Phase 2b Phase 2b initiated mid May 2015. Partial clinical hold lifted October 2015
$17.03
-0.16  -0.93%
$460.63M
27,048,000
9.39
08/13/2016
Tap to view 4 drugs
Drug Indication Stage News
BPX-401 Hematological cancers that express the CD19 antigen Phase 1/2 Phase 1/2 planned 2H 2016
BPX-501 Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer Phase 1/2 Phase 1/2 interim data presented April 2016
BPX-601 Pancreatic cancer Phase 1/2 Phase 1/2 planned
BPX-701 PRAME (preferentially-expressed antigen in melanoma) -expressing melanoma, sarcomas and neuroblastoma cancer Phase 1/2 Phase 1/2 planned
$1.63
-0.03  -1.81%
$23.80M
14,599,000
0.51
08/14/2016
Tap to view 3 drugs
Drug Indication Stage News
INOpulse delivery device Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF) Phase 2 Phase 2 initiated May 2016
INOpulse delivery device Pulmonary Arterial Hypertension (PAH) Phase 3 Phase 3 commenced enrollment June 2016
INOpulse delivery device Pulmonary Hypertension associated with COPD (PH-COPD) Phase 2 Phase 2 to be initiated 3Q 2016. Data due by end of 2016
$0.91
-0.06  -5.54%
$51.06M
56,423,000
0.85
08/14/2016
Tap to view 5 drugs
Drug Indication Stage News
BL-7010 Gluten sensitivity Efficacy study to be initiated later in 2016
BL-8040 Consolidation treatment for AML cancer patients Phase 2b Phase 2b initiated August 2015. Enrollment continues as of August 2016
BL-8040 Mobilization and collection of bone marrow stem cells Phase 2 Phase 2 trial initiated March 2016. Partial data due by end of 2016 with topline data due by the end of 2017
BL-8040 Acute myeloid leukemia (AML) cancer relapsed and refractory Phase 2 Phase 2 data released March 2016. Full set of data to be presented September 7-10, 2016
BL-8040 in combination with KEYTRUDA Pancreatic cancer Phase 2 Phase 2 to be initiated 3Q 2016
$49.97
-0.29  -0.58%
$1.86B
37,169,000
8.89
08/14/2016
Tap to view 4 drugs
Drug Indication Stage News
Lenti-D Childhood cerebral adrenoleukodystrophy (CCALD) Phase 2/3 Phase 2/3 trial initiated October 2013. Interim data released at AAN Conference April 20, 2016.
LentiGlobin β-Thalassemia Phase 1/2 Update expected at ASH December 2016
LentiGlobin - HGB-206 Sickle disease Phase 1/2 Update expected at ASH December 2016
LentiGlobin - HGB-207 non-β0/β0 transfusion-dependent thalassemia (TDT) Phase 3 Phase 3 trial to be initiated 2H 2016
$94.97
-0.16  -0.17%
$15.52B
163,465,000
2.70
08/14/2016
Tap to view 7 drugs
Drug Indication Stage News
BMN 270 Hemophilia A Phase 1/2 Phase 1/2 interim data released July 2016. Phase 2b to be initiated mid 2017
Cerliponase alfa Batten Disease PDUFA PDUFA date January 27 2017
Kyndrisa Duchenne Muscular Dystrophy (DMD) CRL CRL issued January 14 2016
PEG-PAL Phenylketonuria (PKU) BLA Filing Phase 3 data released March 2016. Primary endpoint hit. Key secondary endpoint missed. NDA (BLA) filing to be filed 4Q 2016 or 1Q 2017
Reveglucosidase alfa (BMN 701) Pompe Disease Phase 2 Program terminated June 2016
Vimizim (GALNS) (MPS IVA) Morquio A Syndrome Approved Approved Feb 14 2014
Vosoritide Achondroplasia Phase 2 Phase 2 data released April 2016. Phase 3 trial to be initiated end of 2016
$0.11
+0  +2.12%
$32.25M
302,500,000
0.00
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
MCNA Non-muscle invasive bladder cancer patients who have failed BCG therapy CRL CRL February 2 2016. Further trials required
$1.89
-0.03  -1.06%
$13.85M
7,326,000
0.37
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
TT-034 Hepatitis C Phase 1/2 Announced late February 2016 plans to discontinue development
$0.80
-0.05  -4.87%
$23.06M
28,863,000
0.96
08/25/2016
Tap to view 2 drugs
Drug Indication Stage News
BPX-01 Acne Phase 2b Phase 2b to be initiated August 2016. Data due 1H 2017
BPX-03 Moderate to severe periodic breast pain associated with FBC (fibrocystic breast condition) and cyclic mastalgia Phase 3 Phase 3 to be initiated in 2017
$36.44
-0.11  -0.3%
$255.52M
7,012,000
4.70
08/13/2016
Tap to view 4 drugs
Drug Indication Stage News
XIAFLEX Plantar fibromatosis Phase 2 Phase 2 to commence 4Q 2016
XIAFLEX Human lipomas Phase 2 Phase 2 topline data released June 2016 - endpoints met
XIAFLEX Edematous fibrosclerotic panniculopathy (“cellulite”) Phase 2b Phase 2b initiated February 2016 by partner Endo
XIAFLEX Adhesive Capsulitis (“Frozen Shoulder syndrome”) Phase 2b Phase 2b trial did not meet endpoint. Additional trial to commence in 3Q 2016
$2.98
-0.06  -1.97%
$302.97M
101,667,000
22.59
08/15/2016
Tap to view 3 drugs
Drug Indication Stage News
AST-OPC1 Cervical spinal cord injury Phase 1/2 Phase 1/2 topline data due January 2017
AST-VAC1 Maintenance of relapse-free-survival in acute myeloid leukemia (AML) Phase 3 Phase 3 planned
OpRegen Dry age-related macular degeneration (AMD) Phase 1/2 Phase 2 second cohort underway. Third cohort to be initiated by the end of 2016, pending positive data.
$3.73
+0  +0%
$12.60M
3,377,000
65.86
08/20/2016
Tap to view 1 drug
Drug Indication Stage News
M-001 Universal flu vaccine Phase 2b Phase 2b enrolment commenced March 2016. Data are due late 1H 2017
$3.16
+0.02  +0.64%
$61.59M
19,489,000
3.03
08/05/2016
Tap to view 1 drug
Drug Indication Stage News
CB-839 + nivolumab Phase 1/2 Phase 1/2 enrolment commenced August 2016
$2.37
-0.09  -3.66%
$32.56M
13,740,000
2.86
08/27/2016
Tap to view 5 drugs
Drug Indication Stage News
CF101 Glaucoma Phase 2 Phase 2 failed to meet endpoint - July 2016
CF101 Rheumatoid arthritis Phase 3 Phase 3 planned. Protocol to be submitted 1Q 2017.
CF101 Psoriasis Phase 2/3 Phase 2/3 trial did not meet primary endpoint late March 2015. Meeting to discuss planned Phase 3 trial set for 3Q 2016.
CF101 Non-alcoholic steatohepatitis (NASH) Phase 2 Phase 2 planned. Protocol to be filed 2H 2016
CF102 Cancer - advanced liver cancer second line Phase 2 Phase 2 enrolment to be completed 2H 2016
$3.40
-0.16  -4.49%
$61.04M
17,954,000
3.14
08/16/2016
Tap to view 3 drugs
Drug Indication Stage News
CAP-1002 ALLSTAR Myocardial infarction (heart attack) Phase 2 Phase 2 enrolling. 6 month data due 1Q 2017
CAP-1002 HOPE-Duchenne Duchenne Muscular Dystrophy (DMD) Phase 1/2 Phase 1/2 data due 1Q 2017
Cenderitide Ambulatory heart failure Phase 2 Phase 2 completed. Waiting on data from additional study to determine future
$5.50
-0.06  -1.08%
$150.05M
27,282,000
2.13
08/06/2016
Tap to view 3 drugs
Drug Indication Stage News
CR845 Osteoarthritis (OA) of the knee or hip Phase 2b Phase 2b trial to be initiated 3Q 2016
IV CR845 Acute pain Phase 3 Phase 3 initiated September 2015. Placed on clinical hold February 2016. Clinical hold released April 2016 with enrolment resuming June 2016
IV CR845 Uremic pruritus Phase 2 Phase 2/3 program initiated June 2016
$1.15
-0.01  -0.86%
$155.61M
135,310,000
5.57
08/15/2016
Tap to view 2 drugs
Drug Indication Stage News
ONT-380 + Herceptin and Xeloda HER2+ Metastatic Breast Cancer (MBC) Phase 2 Phase 2 combination trial initiated February 2016. Continues to enroll as of August 2016
ONT-380 and T-DM1 HER2+ Metastatic Breast Cancer (MBC) Phase 1b Phase 1b updated data released at ASCO 2016. Further data due by end of 2016
$1.13
+0  +0%
$55.89M
49,457,000
2.63
07/25/2016
Tap to view 3 drugs
Drug Indication Stage News
ENMD-2076 Cancer - Advanced/Metastatic Soft Tissue Sarcoma Phase 2 Phase 2 initiated Jan 2013. Ongoing as of Nov 2015
ENMD-2076 Cancer - triple-negative breast cancer Phase 2 Phase 2 initiated Jul 2012. Ongoing as of Nov 2015
ENMD-2076 Cancer - fibrolamellar carcinoma (FLC). Phase 2 Phase 2 initiated October 2015
$4.97
+0.06  +1.22%
$76.44M
15,381,000
11.45
08/13/2016
Tap to view 2 drugs
Drug Indication Stage News
CAT-1004 Duchenne muscular dystrophy (DMD) Phase 2 Phase 2 data due late 2016
CAT-2054 Hypercholesterolemia Phase 2a Phase 2a did not meet primary endpoint - June 2016
$2.31
+0.05  +2.21%
$54.16M
23,447,000
4.68
08/15/2016
Tap to view 2 drugs
Drug Indication Stage News
Arhalofenate Gout Phase 3 Phase 3 planned - partner required
MBX-8025 Primary biliary cholangitis (PBC) Phase 2 Phase 2 top-line data released late May 2016. Second trial to be initiated by end of 2016
$2.09
-0.01  -0.35%
$22.99M
10,987,000
20.36
08/15/2016
Tap to view 2 drugs
Drug Indication Stage News
CBLB612 - Russia trial Breast cancer Phase 2 Phase 2 ongoing
Entolimod - Russia trial Neo-adjuvant therapy in treatment-naïve patients with primary colorectal cancer Phase 2 Phase 2 being prepared for analysis
$0.53
-0  -0.47%
$13.96M
26,335,000
1.61
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
Hydros-TA Osteoarthritis of the knee Phase 3 Not pursuing further development
$4.84
+0.2  +4.3%
$231.17M
47,762,000
10.98
08/15/2016
Tap to view 5 drugs
Drug Indication Stage News
CCX140 Diabetic nephropathy Phase 2 Phase 2 topline data released Dec 12 2014. End of Phase 2 meeting planned with FDA
CCX168 atypical Hemolytic Uremic Syndrome (aHUS) Phase 2 Phase 2 data due 2016
CCX168 Associated vasculitis (AAV) Phase 2 Phase 3 to be initiated by the end of 2016.
CCX872 Non-resectable pancreatic cancer Phase 1b Phase 1b early response data due mid 2016. Initial PFS data due 2H 2016
Vercirnon CCX282 Crohn’s disease Phase 3 Partner required to continue with Phase 3 program
$10.97
-0.32  -2.83%
$152.55M
13,906,000
7.09
08/13/2016
Tap to view 2 drugs
Drug Indication Stage News
CD101 IV - STRIVE Candidemia Phase 2 Phase 2 initiated June 2016
CD101 Topical - RADIANT Vulvovaginal candidiasis (VVC) Phase 2 Phase 2 initiated June 2016
$21.08
-0.11  -0.52%
$1.10B
51,991,000
14.06
08/13/2016
Tap to view 6 drugs
Drug Indication Stage News
CEM-101 (solithromycin ) Uncomplicated urogenital gonococcal infections Phase 3 Phase 3 initiated August 2014. Enrolment completed December 2015 but decided to increase enrolment. Ongoing as of August 2016
Solithera - intravenous Community-acquired bacterial pneumonia (CABP) PDUFA PDUFA December 28 2016
Solithera - oral Community-acquired bacterial pneumonia (CABP) PDUFA PDUFA December 27 2016
Solithromycin NASH Phase 2 Phase 2 interim data due 4Q 2016
Solithromycin COPD Phase 2 Phase 2 ongoing as of August 2016
Taksta Acute bacterial skin and skin structure infections (ABSSSI) Phase 3 Phase 3 initiated December 2015. Trial to be completed 1H 2017
$4.01
-0.38  -8.53%
$34.66M
8,650,000
0.53
08/06/2016
Tap to view 2 drugs
Drug Indication Stage News
CERC-301 Major depressive disorder (MDD) Phase 2 Phase 2 data due 1H 2017
CERC-501 Smoking cessation Phase 2 Phase 2 top-line data due 4Q 2016
$6.60
+0.01  +0.15%
$677.88M
102,709,000
13.75
07/25/2016
Tap to view 2 drugs
Drug Indication Stage News
INTERCEPT Platelets Approved PMA approved Dec 18 2014
INTERCEPT B123 Plasma Approved PMA approved Dec 16 2014
$1.11
-0.01  -0.89%
$30.40M
27,384,000
0.66
08/18/2016
Tap to view 4 drugs
Drug Indication Stage News
CRLX101 and Avastin - RCC Trial 3rd and 4th line Relapsed Renal Cell Carcinoma cancer Phase 2 Phase 2 data released August 2016 failed to meet primary endpoint
CRLX101 and paclitaxel Platinum-resistant ovarian cancer Phase 2 Further interim data due at the 2016 European Society for Medical Oncology (ESMO) Congress 7-11 October 2016
CRLX101 in Combination with Chemotherapy and Radiation Renal Cell Carcinoma cancer Phase 2 Initial data released mid March 2015. Further interim data due 2H 2016
CRLX101, in combination with LYNPARZA Solid tumors - cancer Phase 1/2 Phase 1/2 trial commenced dosing May 2016. Top-line data due 1H 2017
$2.20
-0.01  -0.46%
$91.39M
41,539,000
5.34
08/15/2016
Tap to view 1 drug
Drug Indication Stage News
CF-301 Serious infections caused byStaph aureus including MRSA Phase 2 Phase 2 to be initiated 4Q 2016 with data due 2Q 2018
$2.63
-0.01  -0.38%
$64.06M
24,356,000
24.63
08/15/2016
Tap to view 3 drugs
Drug Indication Stage News
Mycapssa Acromegaly CRL CRL April 15 2016
Mycapssa Neuroendocrine tumors (NET) Phase 2 Phase 2 planned
Oral octreotide Neuroendocrine tumors (NET) Phase 2 Phase 2 to be initiated late 2016
$29.35
+0.4  +1.38%
$1.27B
43,380,000
10.17
08/13/2016
Tap to view 4 drugs
Drug Indication Stage News
CHS-0214 Psoriasis Phase 3 Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
CHS-131 Relapsing remitting multiple sclerosis (RRMS) Phase 2b Phase 2b data released June 2016
CHS-1420 Psoriasis Phase 3 Phase 3 top-line data met endpoints August 2016. Full data due 4Q 2016 with BLA filing to follow.
CHS-1701 Pegfilgrastim biosimilar BLA Filing BLA filed August 9 2016
$4.95
-0.2  -3.88%
$29.27M
5,914,000
2.61
08/15/2016
Tap to view 2 drugs
Drug Indication Stage News
CLBS03 Type 1 diabetes Phase 2 Phase 2 initiated March 2016. Interim data due by the end of 2016
CLBS20 Metastatic melanoma Phase 3 Announced January 2016 that Phase 3 trial has been discontinued
$8.65
+0.45  +5.49%
$132.64M
15,334,000
2.79
08/27/2016
Tap to view 2 drugs
Drug Indication Stage News
Lasmiditan - SAMURAI Migraine Phase 3 Phase 3 top-line data available week of September 5. September 9 listed as last possible date.
Lasmiditan - SPARTAN Migraine Phase 3 Phase 3 top-line data due mid 2017
$3.47
-0.03  -0.86%
$348.89M
100,545,000
13.04
08/15/2016
Tap to view 9 drugs
Drug Indication Stage News
CDX-014 Renal cell carcinoma (RCC) - cancer Phase 1/2 Phase 1/2 initiated July 2016
CDX-110 (rindopepimut) in combination with Avastin - ReACT Glioblastoma multiforme (GBM) refractory cancer Phase 2 Phase 2 endpoint met - ASCO 2015
CDX-110 rindopepimut - ACT IV Cancer- glioblastoma multiforme (GBM) front line Phase 3 Trial discontinued early March 2016 as unlikely to meet primary endpoint
Glembatumumab vedotin Squamous cell lung cancer Phase 1/2 Phase 1/2 commenced April 2016
Glembatumumab vedotin Metastatic triple negative breast cancers that overexpress gpNMB Phase 2a Phase 2b enrolment to be completed by end of 2016
Glembatumumab vedotin Cancer - melanoma Phase 2 Phase 2 initiated December 2014. Data to be at the European Society for Medical Oncology (ESMO) Congress in October 2016
Varlilumab and atezolizumab (anti-PDL1) Renal cell carcinoma (RCC) cancer Phase 1/2 Phase 2 part of trial to be initiated 3Q 2016
Varlilumab and nivolumab Solid tumors - cancer Phase 2 Phase 2 initiated April 2016
Varlilumab and sunitinib (Sutent) Clear cell renal cell carcinoma (CC-RCC) cancer Phase 1/2 Enrolling
$7.20
+0.07  +0.98%
$147.92M
20,545,000
0.93
08/03/2016
Tap to view 3 drugs
Drug Indication Stage News
CLS-1001 Macular edema associated with non-infectious uveitis Phase 3 Phase 3 data due 2H 2017
CLS-1002 Wet age-related macular degeneration (Wet-AMD) Phase 1/2 Phase 1/2 trial to be initiated following IND submission 2H 2016
Zuprata - CLS-1003 Macular edema associated with retinal vein occlusion (RVO) Phase 2 End of Phase 2 meeting planned for 2H 2016. Phase 3 trial to commence 1H 2017 pending positive outcome from meeting
$1.23
-0.04  -3.15%
$31.75M
25,810,000
5.91
07/25/2016
Tap to view 3 drugs
Drug Indication Stage News
GEN-1 OVATION Ovarian cancer Phase 1b Phase 1b initiated October 2015
ThermoDox Hepatocellular carcinoma - liver cancer Phase 3 Failed to meet primary endpoint. New Phase 3 enrolment to be completed late 2017 or early 2018
ThermoDox - Dignity Recurrent Chest Wall Breast Cancer (RCWBC) Phase 2 Final data released December 2015
$22.73
+0.37  +1.65%
$875.13M
38,501,000
8.02
08/24/2016
Tap to view 5 drugs
Drug Indication Stage News
Lucitanib Breast cancer Phase 2 Development discontinued
Rociletinib Mutant EGFR T790M-positive lung cancer CRL PDUFA date was June 28, 2016. Company expect CRL. Phase 3 TIGER-3 also terminated
Rociletinib in combination with atezolizumab EGFR-mutant non-small cell lung cancer Phase 1b Phase 1b/2 trial initiated January 2016
Rucaparib ARIEL2 Cancer - ovarian second line PDUFA priority review PDUFA date under priority review February 23, 2017
Rucaparib ARIEL3 Ovarian cancer patients with a BRCA-like mutation Phase 3 Pivotal trial initiated late 2013. Enrolment completed 2Q 2016. Data due 4Q 2017
$4.49
-0.29  -6.07%
$207.50M
46,214,000
10.24
07/25/2016
Tap to view 4 drugs
Drug Indication Stage News
Brincidofovir - Advise trial Adenovirus Infection Phase 3 Phase 3 interim analysis released May 2016
Brincidofovir - SUPPRESS Cytomegalovirus (CMV) infection following an allogeneic hematopoietic stem cell transplant (HSCT) Phase 3 Phase 3 endpoints not met December 2015
Brincidofovir - SURPASS Cytomegalovirus (CMV) infection Phase 3 Phase 3 discontinued following poor data from SUPPRESS trial
Brincidofovir - SUSTAIN Cytomegalovirus (CMV) infection Phase 3 Phase 3 discontinued following poor data from SUPPRESS trial
$1.94
+0.01  +0.52%
$42.82M
22,072,000
2.78
08/04/2016
Tap to view 5 drugs
Drug Indication Stage News
Emricasan Acute-on-Chronic Liver Failure (ACLF) Phase 2 Phase 2 topline data released Jan 2015
Emricasan Portal Hypertension Phase 2 Phase 2 data released September 2015.
Emricasan Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT) Phase 2a Phase 2b initiated May 2014. Topline data due 1H 2018
Emricasan NASH fibrosis - ENCORE-NF trial Phase 2 Phase 2 trial initiated January 2016. Data are due 2018
Emricasan Liver Cirrhosis Phase 2 Phase 2 topline data released early January 2016
$10.63
-0.01  -0.09%
$236.27M
22,227,000
4.74
08/15/2016
Tap to view 4 drugs
Drug Indication Stage News
AVP-786 Major depressive disorder Phase 2
AVP-786 Agitation in patients with Alzheimer’s disease Phase 3 Phase 3 initiated December 2015. Trial to be completed 3Q 2018
CTP-499 Diabetic Kidney Disease Phase 2 Phase 3 planned. Needs partner
CTP-656 Cystic fibrosis Phase 2 Phase 2 planned for 2H 2016
$10.22
-0.31  -2.94%
$240.46M
23,528,000
12.11
08/13/2016
Tap to view 1 drug
Drug Indication Stage News
Xtampza ER (oxycodone) Severe pain Approved Approved April 26 2016
$5.45
-0.05  -0.91%
$602.74M
110,594,000
22.13
08/15/2016
Tap to view 5 drugs
Drug Indication Stage News
CORT125134 Solid tumors - cancer Phase 2 Phase 2 initiated 1Q 2016
CORT125134 Cushing’s syndrome Phase 2 Phase 2 trial initiated 2Q 2016
Mifepristone in combination with eribulin Cancer - triple-negative breast cancer Phase 1/2 Phase 1/2 data due 3Q 2017
Mifepristone plus Abraxane Triple-negative breast cancer Phase 2 Phase 2 planned
Mifepristone plus enzalutamide Castration-resistant prostate cancer (CRPC) Phase 2 Phase 2 enrolling
$1.08
+0.02  +1.89%
$89.50M
82,870,000
4.02
08/13/2016
Tap to view 2 drugs
Drug Indication Stage News
Firdapse Congenital Myasthenic Syndromes (CMS) Phase 3 Phase 3 data due 2H 2017
Firdapse Lambert-Easton Myasthenic Syndrome (LEMS) Phase 3 Refusal to file letter reported on Feb 17 2016 for Dec 2015 NDA Filing. Additional Phase 3 trial planned for 4Q 2016. Data due 2H 2017
$3.82
+0.16  +4.37%
$167.12M
43,748,000
0.79
08/16/2016
Tap to view 4 drugs
Drug Indication Stage News
Resunab Cystic Fibrosis Phase 2 Phase 2 data due 4Q 2016
Resunab Systemic lupus erythematosus (SLE) Phase 2 Phase 2 trial to be initiated 1H 2017
Resunab Dermatomyositis Phase 2 Phase 2 to complete enrollment 2Q 2017
Resunab Systemic Sclerosis Phase 2 Phase 2 data due 4Q 2016
$1.70
+0.03  +1.8%
$220.10M
129,472,000
10.68
08/05/2016
Tap to view 1 drug
Drug Indication Stage News
CUDC-907 Diffuse-large B-cell lymphoma (DLBCL) Phase 2 Phase 2 data due 2017
$1.58
-0.03  -1.86%
$58.76M
37,187,000
13.09
08/15/2016
Tap to view 2 drugs
Drug Indication Stage News
Neutrolin - LOCK-IT 100 Hemodialysis patients with central venous catheters Phase 3 Phase 3 enrolment to be completed in 2016. Interim analysis due 4Q 2016 with Phase 3 data due 3Q 2017
Neutrolin - LOCK-IT 200 Oncology patients on Total Parental Nutrition (TPN) Phase 3 Phase 3 to be initiated pending funding
$13.88
+0.19  +1.39%
$290.22M
20,909,000
7.40
08/15/2016
Tap to view 1 drug
Drug Indication Stage News
CPI-444 Solid tumors - cancer Phase 1b Phase 1/1b enrolling
$0.35
-0.01  -2.77%
$96.46M
279,604,000
0.93
08/15/2016
Tap to view 3 drugs
Drug Indication Stage News
OPAXIO Ovarian cancer Phase 3 Phase 3 - noted July 2016 that unlikely to have survival benefit
Pacritinib Myelofibrosis Phase 3 PERSIST-2 data due 3Q 2016. Currently on clinical hold
Tosedostat Older patients with AML or high-risk myelodysplastic syndrome (MDS) - cancer Phase 2 Phase 3 trial potentially starting in 2016, depending on discussions with FDA
$1.37
+0.01  +0.74%
$167.88M
122,540,000
0.00
08/15/2016
Tap to view 5 drugs
Drug Indication Stage News
Brilacidin Oral mucositis Phase 2 Phase 2 ongoing
Brilacidin Ulcerative proctitis Phase 2 Phase 2 ongoing
Brilacidin Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Phase 2 Phase 3 planned
Cellceutix Placque psoriasis Phase 2 Phase 2b trial to be initiated late 3Q or early 4Q 2016. Data due 2Q 2017
Kevetrin Ovarian cancer Phase 2 Phase 2 to commence 4Q 2016
$1.12
-0.01  -0.88%
$36.10M
32,231,000
6.55
08/15/2016
Tap to view 2 drugs
Drug Indication Stage News
CMX157 Hepatitis B Phase 2 Phase 2 dosing initiated June 2016. Trial to be completed 4Q 2016
FV-100 Shingles Phase 3 Phase 3 ongoing
$0.26
-0.02  -5.31%
$29.26M
114,760,000
14.98
08/14/2016
Tap to view 4 drugs
Drug Indication Stage News
NSI-566 Amyotrophic lateral sclerosis (Lou Gehrig’s) Phase 2 Phase 2 data released early March 2015. A larger controlled Phase 2 trial is dependent on funding
NSI-189 Cognitive deficit in schizophrenia Phase 1b Phase 1b to be initiated 2016
NSI-189 Major depressive disorder Phase 2 Phase 2 initiated March 2016. Data are due 2H 2017
NSI-566 Motor deficits due to ischemic stroke Phase 1/2 Phase 1 portion of the trial completed
$0.47
-0.02  -3.86%
$68.47M
145,349,000
18.04
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
Multikline Head and Neck cancer Phase 3 Initiated Dec 2010. Full enrolment due to be completed 2016
CYAD Celyad SA
$25.09
-1.96  -7.25%
$233.66M
9,313,000
2.76
08/02/2016
Tap to view 1 drug
Drug Indication Stage News
C-Cure - Chart 1 trial Chronic Heart Failure secondary to ischemic cardiomyopathy Phase 3 Phase 3 data did not meet primary endpoint
$6.83
-0.22  -3.12%
$21.30M
3,118,000
2.60
08/13/2016
Tap to view 2 drugs
Drug Indication Stage News
Sapacitabine (SEAMLESS) Acute myeloid leukemia - cancer Phase 3 Noted mid-Dec 2014 that interim analysis suggests that trial will fail. Top-line data due around 4Q 2016
Seliciclib Cushing’s disease Phase 2 Phase 2 ongoing
$18.43
+0.12  +0.66%
$228.73M
12,411,000
2.92
08/15/2016
Tap to view 2 drugs
Drug Indication Stage News
APL-130277 - CTH-300 OFF episodes in patients with Parkinson’s disease Phase 3 Phase 3 top-line data due towards end of 3Q or early 4Q 2016
APL-130277 - CTH-301 Safety trial OFF episodes in patients with Parkinson’s disease Phase 3 Phase 3 top-line safety data due 1H 2017
$12.10
+0.2  +1.68%
$480.41M
39,703,000
13.55
08/18/2016
Tap to view 4 drugs
Drug Indication Stage News
CK-2127107 Spinal muscular atrophy (SMA) Phase 2 Phase 2 initiated January 2016. Enrollment to be completed 2H 2016. Data are due 1H 2017
CK-2127107 Chronic obstructive pulmonary disease (COPD) Phase 2 Phase 2 initiated June 2016. Data due 2017
Omecamtiv mecarbil ATOMIC-AHF Acute heart failure Phase 2b Phase 2 released October 2015. Phase 3 to be possibly initiated in 2016. Decision to be made in 3Q 2016
Tirasemtiv ALS Phase 3 Phase 3 enrollment completed August 2016. Data are due 2H 2017
$0.59
+0.02  +3.44%
$57.20M
96,943,000
1.88
08/13/2016
Tap to view 5 drugs
Drug Indication Stage News
Aldoxorubicin Cancer - AIDS-related Kaposi’s sarcoma Phase 2b Phase 2b ongoing
Aldoxorubicin Cancer - soft tissue sarcomas first line Phase 2a Overall survival data - secondary endpoint released Jan 2015 - HR 0.73 CI 0.44-1.20 - OS 16.0 months vs 14.4 (p=0.21) - not statistically significant
Aldoxorubicin Cancer - unresectable glioblastoma Phase 2 Phase 2 overall survival data due 2H 2016. Updated interim data at ASCO 2016
Aldoxorubicin Relapsed/refractory small cell lung cancer Phase 2a Phase 2b data due 4Q 2016
Aldoxorubicin with doxorubicin Soft tissue sarcomas refractory cancer Phase 3 Phase 3 PFS data released July 2016 showed no significant improvement in PFS. Second analysis due 4Q 2016
$2.03
-0.04  -1.93%
$41.60M
20,492,000
3.56
08/14/2016
Tap to view 4 drugs
Drug Indication Stage News
Cell Enriched Adipose Early stage female and male pattern hair loss Phase 2